OVERVIEW

Deprescribing Anticholinergic Medications in Schizophrenia is organized by University of Pittsburgh Medical Center (UPMC).

Release Date: 04/9/2020
Expires: 04/2/2021

Accreditation:
The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded (0.075) continuing education units (CEU) which are equivalent to .75 contact hour.

Educational Objectives:
Upon completion of this activity, participants should be able to:
• Identify the pharmacology of anticholinergic medications, including peripheral and central effects
• Recognize anticholinergic burden and impact on clinical outcomes
• Describe how reducing anticholinergic medications for EPS can improve clinical outcomes and quality of life in patients on antipsychotics

Additional details will be posted as soon as information is available.